Profound Medical (PROF.US) Financial Statements - Balance Sheet/Income Statement/Cash Flow - Longbridge

Quote List Quote List

Event Tracking

Nov28

Profound Medical Launches TULSA-AI Volume Reduction Module and Showcases New Clinical Data for TULSA-PRO

12:45

Nov16

Profound Medical Reports Q3 Earnings with 87% Revenue Growth, but Uncertainty Looms Over Financing Strategy

00:06

Nov14

Stifel Nicolaus analyst maintains buy rating on Profound Medical with a target price of $12

13:47

Profound Medical released FY2025 9 Months Earnings on November 13 After-Market EST, with actual revenue of USD 10.12 M and EPS of USD -1.1441

00:00

Profound Medical released FY2025 Q3 earnings on November 13 After-Market EST, actual revenue USD 5.289 M (forecast USD 5.084 M), actual EPS USD -0.2649 (forecast USD -0.376)

00:00

Nov10

Profound Medical Regains Exclusive Distribution Rights of TULSA-PRO in Canada

21:30

Schedules & Filings

Schedules

Filings

Nov13

Earning Release(EST)

FY2025 Q3 Earning Release (USD) Revenue 5.289 M, Net Income -7.977 M, EPS -0.2649

Aug14

Earning Release(EST)

FY2025 Q2 Earning Release (USD) Revenue 2.211 M, Net Income -15.7 M, EPS -0.5222

May8

Earning Release(EST)

FY2025 Q1 Earning Release (USD) Revenue 2.621 M, Net Income -10.72 M, EPS -0.3569

View More

Stock List

Top Gainers

Top Decliners

China Concepts

Symbol

Price

%Chg

Change

View More